Pro basketball player Max Strus kicks off the new season with improved vision thanks to life-changing EVO ICL lenses

LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion eye delivery systems, today announced a partnership with professional basketball player Max Strus to continuing its mission to bring EVO Implantable Collamer® Lenses (EVO) to the millions of Americans who suffer from nearsightedness or nearsightedness. EVO is an FDA cleared vision correction lens designed for the correction/reduction of myopia with or without astigmatism. In August, Strus, with a prescription of less than (-5) diopters, had EVO lenses implanted by his doctor (EVO procedure) to finally end the frustrations of glasses and contact lenses that have plagued him since 5th grade. year.

Like most athletes, Max Strus is preparing for the upcoming season by giving himself every advantage possible to improve his competitive edge. As part of his preparation, he decided to undergo the EVO procedure, which involved adding a small flexible lens to both eyes to correct his distance vision. Following the EVO procedure, he went from struggling with the hassle of contact lenses, both on and off the field, to seeing better than 20/20 clear vision. EVO is different from other vision correction procedures, such as LASIK, because it provides crisp, clear vision day and night while preserving the cornea.2.3 If desired, EVO lenses can also be removed by a doctor for added peace of mind.

“I’ve struggled in the field for a long time with my contact lenses, whether dealing with the discomfort of seasonal allergies or worrying that one of my contacts might accidentally come out while playing,” said Max Strus. “After learning about vision correction options from my doctor, one of the main reasons I chose EVO over other options was knowing that it could be removed by a doctor if ever I I wanted to, and it gave me incredible peace of mind. I’m so excited to start the season with 20/10 vision!

Team ophthalmologist William Trattler, MD, who evaluated Max Strus for the EVO procedure and performed the pre and post-operative care, said, “Max Strus requested EVO lenses and it’s fantastic that he now has vision better than 20/20 (20/10) for his mild myopia (less than -5.0 diopters) As such, it’s no surprise that he is incredibly happy with the results, and I am also delighted for him. I expect great things for him and the team this season.”

Starting this month, Max Strus will share his journey in national and social media campaigns which will then expand globally. The campaigns are initially designed to help educate and raise awareness about EVO among the millions of Americans who suffer from myopia and are looking for a proven and effective vision correction solution. Myopia is the most common eye disorder in the world and its prevalence is increasing rapidly. It is estimated that more than 30% of the world’s population (2.6 billion people) suffer from myopia and this number is expected to reach 50% of the world’s population by 2050.1

“Dealing with the downsides of eyeglasses and contact lenses is a challenge for everyone, but it’s especially frustrating for athletes who rely on their vision to compete and excel,” said Caren Mason, President and CEO of direction of STAAR Surgical. “Max Strus is one of the first of what we believe to be many professional athletes to have EVO lenses implanted, and we are thrilled to help him improve his vision just in time for the start of the season. We know her story will help so many people with vision correction needs – whether they are an athlete, an adventurer or just want to enjoy visual freedom every day.

EVO lenses can permanently correct/reduce myopia and astigmatism without removing corneal tissue and, if desired, can be removed by a physician for added peace of mind. The EVO procedure involves implanting (or adding) a proprietary, biocompatible, flexible lens made from Collamer® into the eye between the iris (colored part of the eye) and the natural lens to correct/reduce myopia with or without astigmatism. The EVO procedure takes approximately 20-30 minutes for each eye. The EVO lens works in harmony with the natural eye while providing crisp, clear vision, excellent night vision, built-in UV protection and does not induce dry eye syndrome.2,3,4 Most patients see their vision improve immediately after the procedure.

Although the EVO ICL lens is new to the US market, it has been successfully approved, marketed and implanted by ophthalmologists in Europe, Asia and the rest of the world. According to a patient survey, 99.4% of patients would undergo the EVO ICL procedure again.5 Over 2,000,000 ICLs have been delivered worldwide.

For more information on EVO Implantable Collamer® lenses, visit https://EVOICL.com.

References:

1)

Holden B, Frick T, Wilson D et al. Global prevalence of myopia and high myopia and temporal trends from 2000 to 2050 (Ophthalmology 2016;123:1036-1042).

2)

Martinez-Plazs E, Lopez-Miguel A, Lopez-De La Rosa A, et al. Effect of EVO+ Visian Phakic implantable Collamer lens on visual performance and quality of vision and life, Am J Ophthalmol 2021;226:117–125.

3)

Parkhurst GD. A prospective comparison of phakic collamer lenses and optimized wavefront laser-assisted in situ keratomileusis for the correction of myopia. Clin Ophthalmol. 2016 Jun 29;10:1209-15.

4)

Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented at the American Society of Cataract and Refractive Surgery (ASCRS) 2012.

5)

Packer M. The central-port implantable Collamer lens: review of the literature. Clinical Ophthalmology 2018: 12: 2427–2438.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable eye lenses with companion delivery systems. These lenses are intended to provide visual freedom to patients, reducing or eliminating the need for glasses or contact lenses. All of these lenses are bendable, allowing the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is referred to as the Implantable Collamer® or “ICL” lens, which includes the EVO Visian ICL™ product line. Over 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL, visit: EVOICL.com. Based in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the company’s website at www.staar.com.

Safe Harbor

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: the safety, efficacy, or performance of the product for a particular patient, and any statement of assumption underlying one of the preceding elements. Important factors that could cause actual results to differ materially from those indicated by these forward-looking statements include the risk factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 under under “Risk Factors”, which is filed with the Securities and Exchange Commission and available in the “Investor Information” section of the Company’s website under “SEC Filings”. We disclaim any intention or obligation to update or revise any forward-looking statements as a result of new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements.

Important safety information for EVO ICL

The EVO Visian ICL lens is intended to correct/reduce myopia between -3.0D to -20.0D and to treat astigmatism from 1.0D to 4.0D. If you have myopia in these ranges , EVO Visian ICL surgery can improve your distance vision without glasses. or contact lenses. Because the EVO Visian ICL corrects distance vision, it does not eliminate the need for reading glasses, you may need them at some point, even if you have never worn them before. Because the implantation of the EVO Visian ICL is a surgical procedure, before considering EVO Visian ICL surgery, you should undergo a complete eye examination and discuss EVO Visian ICL surgery with your eye care professional, in particular potential benefits, risks and complications. You should discuss the time needed for healing after surgery. Complications, although rare, can include the need for additional surgery, inflammation, loss of cells from the back surface of the cornea, increased eye pressure, and cataracts. You should NOT have EVO Visian ICL surgery if your doctor determines that 1) your eye shape is not suitable, 2) you do not meet the minimum endothelial cell density for your age at the time of implantation , 3) you have severe glaucoma, 4) your vision is unstable; or 5) if you are pregnant or breastfeeding.

For more information on potential benefits, risks, and complications, please visit DiscoverICL.com.

Comments are closed.